Ignite Creation Date:
2024-05-06 @ 4:06 PM
Last Modification Date:
2024-10-26 @ 2:04 PM
Study NCT ID:
NCT04878913
Status:
COMPLETED
Last Update Posted:
2022-03-25
First Post:
2021-05-04
Brief Title:
Retrospective Evaluation of Lung Pathology in Subjects With COVID-19
Sponsor:
Vicore Pharma AB
Organization:
Vicore Pharma AB
Study Overview
Official Title:
Non-interventional Retrospective Multicenter Follow-up Study Evaluating the Effect of C21 on Lung Pathology in Subjects Previously Hospitalized With COVID-19 and Enrolled in the VP-C21-006 Trial
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ATTRACT-2
Brief Summary:
Non-interventional retrospective multi-center follow-up study evaluating the effect of C21 on lung pathology in subjects previously hospitalised with COVID-19 and enrolled in the VP-C21-006 trial
Detailed Description:
The study will collect available HRCT scans obtained prior to during treatment with C21 or placebo and up to 24 weeks after trial completion
HRCT scans will be assessed for ground glass opacity reticulation band opacity fibrosis and consolidation by a central blinded HRCT reader
HRCT scans will be assessed for ground glass opacity reticulation band opacity fibrosis and consolidation by a central blinded HRCT reader
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None